Literature DB >> 28337510

[Seven years of the National Action League for People with Rare Diseases : NAMSE - a success story?!]

Alexandra Halbach1, Birgit Schnieders2, Karin Knufmann-Happe2.   

Abstract

It is estimated that four million people in Germany are living with a rare disease; in the EU, approximately 30 million people are affected. All rare diseases are chronic, linked to invalidity and/or restricted life expectancy, and their symptoms are often already manifest in childhood. Some 80% of rare diseases are genetically determined; they can rarely be cured. Furthermore, the pathogenesis of many rare diseases is unknown.In a move to ameliorate the situation of persons with rare diseases, the National Action League for People with Rare Diseases (NAMSE) published the National Plan of Action for People with Rare Diseases containing 52 measures that aim to achieve the desired improvements. More than half of these measures have already been implemented or are currently in the process of implementation. The Federal Ministry of Health is supporting this implementation process with numerous projects.NAMSE has achieved a great deal as a result of the National Plan of Action for People with Rare Diseases, even though not all of the measures included in the National Plan of Action have been implemented. The first results of individual measures are already becoming apparent. In order to achieve long-lasting improvements in the prevention, diagnosis and therapy of rare diseases, initiatives will have to be coordinated in the future as well.The Federal Ministry of Health will be funding the NAMSE Coordinating Office until mid-2018, thus ensuring that NAMSE will remain operational until that time. All of the partners collaborating in the Action League agree on the need for NAMSE, together with its coordinating office, to remain in place. To this end, a structure that keeps the health care situation of persons with rare diseases under observation, that suggests solutions and offers a possibility for the parties involved to network, is necessary. The question of conducting a legal restructuring of NAMSE in the future that will be sustainable in the long term is currently under discussion.

Entities:  

Keywords:  Action plan; Centers; NAMSE; Rare diseases; Sustainability

Mesh:

Year:  2017        PMID: 28337510     DOI: 10.1007/s00103-017-2530-0

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  5 in total

1.  Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems.

Authors:  J-Matthias Graf von der Schulenburg; Martin Frank
Journal:  Eur J Health Econ       Date:  2015-03

2.  Parents' experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS).

Authors:  S Somanadhan; P J Larkin
Journal:  Orphanet J Rare Dis       Date:  2016-10-10       Impact factor: 4.123

3.  Quality of health care in adolescents and adults with disorders/differences of sex development (DSD) in six European countries (dsd-LIFE).

Authors:  Ute Thyen; Till Ittermann; Steffen Flessa; Holger Muehlan; Wiebke Birnbaum; Marion Rapp; Louise Marshall; Maria Szarras-Capnik; Claire Bouvattier; Baudewijntje P C Kreukels; Anna Nordenstroem; Robert Roehle; Birgit Koehler
Journal:  BMC Health Serv Res       Date:  2018-07-05       Impact factor: 2.655

4.  Potentials and current shortcomings in the cooperation between German centers for rare diseases and primary care physicians: results from the project TRANSLATE-NAMSE.

Authors:  D Druschke; F Krause; G Müller; J Scharfe; G F Hoffmann; J Schmitt
Journal:  Orphanet J Rare Dis       Date:  2021-11-24       Impact factor: 4.123

5.  Adopting Quality Criteria for Websites Providing Medical Information About Rare Diseases.

Authors:  Frédéric Pauer; Jens Göbel; Holger Storf; Svenja Litzkendorf; Ana Babac; Martin Frank; Verena Lührs; Franziska Schauer; Jörg Schmidtke; Lisa Biehl; Thomas Of Wagner; Frank Ückert; Johann-Matthias Graf von der Schulenburg; Tobias Hartz
Journal:  Interact J Med Res       Date:  2016-08-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.